Video

Dr. Neelapu on Updated ZUMA-1 Findings in Non-Hodgkin Lymphoma

Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the updated findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) for patients with refractory aggressive non-Hodgkin lymphoma.

Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the updated findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) for patients with refractory aggressive non-Hodgkin lymphoma.

ZUMA-1 is a phase II multicenter trial of axicabtagene. which is a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, which enrolled 108 patients with refractory aggressive NHL, Neelapu explains. Eligible patients had no response to their last line or therapy, or they experienced relapse within 12 months after autologous stem cell transplant.

Results presented at the 2017 ASH Annual Meeting include a median follow-up of 15.4 months, with the best ORR of 82% and a best complete remission (CR) rate of 58%. Additionally, 40% patients remain in CR; in the ongoing cohort at 15.4 months, the ORR was 42%. The median overall survival and the median duration of response for the CR patients have not been reached. Currently, 56% of patients remain alive, he concludes.

Related Videos
Minoo Battiwalla, MD, MS
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
David C. Fisher, MD
Alex Herrera, MD